ZA975335B - Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors. - Google Patents

Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors.

Info

Publication number
ZA975335B
ZA975335B ZA9705335A ZA975335A ZA975335B ZA 975335 B ZA975335 B ZA 975335B ZA 9705335 A ZA9705335 A ZA 9705335A ZA 975335 A ZA975335 A ZA 975335A ZA 975335 B ZA975335 B ZA 975335B
Authority
ZA
South Africa
Prior art keywords
mirtazapine
pharmaceutical composition
serotonin reuptake
reuptake inhibitors
selective serotonin
Prior art date
Application number
ZA9705335A
Other languages
English (en)
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA975335(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ZA975335B publication Critical patent/ZA975335B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9705335A 1996-06-19 1997-06-17 Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors. ZA975335B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
ZA975335B true ZA975335B (en) 1998-01-26

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705335A ZA975335B (en) 1996-06-19 1997-06-17 Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors.

Country Status (25)

Country Link
US (1) US5977099A (es)
JP (2) JP4925074B2 (es)
KR (1) KR100481254B1 (es)
CN (1) CN1132581C (es)
AR (1) AR007609A1 (es)
AT (1) ATE213159T1 (es)
AU (1) AU727851B2 (es)
BR (1) BR9703624A (es)
CA (1) CA2208199C (es)
CZ (1) CZ290691B6 (es)
DE (1) DE69710390T2 (es)
DK (1) DK0813873T3 (es)
ES (1) ES2172744T3 (es)
HK (1) HK1006081A1 (es)
HU (1) HU225534B1 (es)
ID (1) ID17051A (es)
IL (1) IL121076A (es)
NO (1) NO313177B1 (es)
NZ (1) NZ328113A (es)
PL (1) PL188520B1 (es)
PT (1) PT813873E (es)
RU (1) RU2181287C2 (es)
SG (1) SG60073A1 (es)
TR (1) TR199700522A3 (es)
ZA (1) ZA975335B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
PT1030667E (pt) * 1997-11-14 2005-06-30 Akzo Nobel Nv Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
EP1251854A2 (en) * 2000-01-19 2002-10-30 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2003079886A2 (en) * 2002-03-21 2003-10-02 Hinz Martin C Serotonin and catecholamine system segment optimization techonology
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1575590B1 (en) * 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
CA2585317C (en) * 2004-11-19 2015-02-24 N.V. Organon Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP5198660B2 (ja) 2009-06-09 2013-05-15 住友重機械工業株式会社 ハイブリッド式ショベル及びその制御方法
KR101414012B1 (ko) * 2009-11-13 2014-07-01 주식회사 녹십자 아릴피페라진-함유 퓨린 유도체 및 그의 용도
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
ATE99943T1 (de) * 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
WO1999017803A1 (en) * 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug

Also Published As

Publication number Publication date
ES2172744T3 (es) 2002-10-01
AR007609A1 (es) 1999-11-10
AU727851B2 (en) 2001-01-04
ATE213159T1 (de) 2002-02-15
BR9703624A (pt) 1998-09-01
AU2612997A (en) 1998-01-08
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
US5977099A (en) 1999-11-02
HU9701068D0 (en) 1997-08-28
CA2208199C (en) 2006-10-24
JP2009137970A (ja) 2009-06-25
TR199700522A2 (xx) 1998-01-21
ID17051A (id) 1997-12-04
KR100481254B1 (ko) 2005-09-12
CN1132581C (zh) 2003-12-31
JP4925074B2 (ja) 2012-04-25
DE69710390T2 (de) 2002-08-14
DK0813873T3 (da) 2002-05-27
JPH1067663A (ja) 1998-03-10
HUP9701068A3 (en) 2000-07-28
PL320628A1 (en) 1997-12-22
CZ187097A3 (cs) 1998-01-14
MX9704579A (es) 1998-07-31
HK1006081A1 (en) 1999-02-12
NZ328113A (en) 1999-09-29
RU2181287C2 (ru) 2002-04-20
KR980000447A (ko) 1998-03-30
HUP9701068A2 (hu) 1998-08-28
CA2208199A1 (en) 1997-12-19
SG60073A1 (en) 1999-02-22
PT813873E (pt) 2002-06-28
PL188520B1 (pl) 2005-02-28
CZ290691B6 (cs) 2002-09-11
CN1173330A (zh) 1998-02-18
IL121076A (en) 2000-10-31
TR199700522A3 (tr) 1998-01-21
NO972816D0 (no) 1997-06-18
NO313177B1 (no) 2002-08-26
DE69710390D1 (de) 2002-03-21
NO972816L (no) 1997-12-22

Similar Documents

Publication Publication Date Title
ZA975335B (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors.
HK1049630A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same.
ZA975947B (en) Aqueous-based pharmaceutical composition.
ZA9711508B (en) Rapidly disintegrable pharmaceutical composition.
ZA9710071B (en) Pharmaceutical composition.
ZA9710927B (en) Pharmaceutical composition.
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
HK1018780A1 (en) 6-Phenylpyridine-2-ylamine derivatives, the composition and use thereof.
ZA973022B (en) New pharmaceutical composition with anaesthetic effect.
HK1027957A1 (en) Pharmaceutical composition.
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
HK1019757A1 (en) Synthetic polysaccharides, preparation method therefor and pharmaceutical compositions containing same.
ZA200005510B (en) Pharmaceutical composition.
HUP0004561A3 (en) Dihydrobenzofurans, pharmaceutical compositions containing them and use thereof
ZA989680B (en) Pharmaceutical composition.
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP0002861A3 (en) Benzothiophene derivatives, and compositions containing the same
HK1048318A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors.
NO984444L (no) Benzothiofener, formuleringer som inneholder de samme og fremgangsmÕter
NO983802D0 (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmÕter
HUP0000203A3 (en) Naphthyl derivatives, pharmaceutical compositions containing them and intermediates
ZA987392B (en) Pharmaceutical composition.
AU1193199A (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1dalpha antagonists
HUP0103006A3 (en) Substituted betha-diketones, pharmaceutical compositions containing them and their use